Drug Trial Radar · NCT07672223
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
586
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Sep 30, 2029
Study completion Nov 30, 2031
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with. with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR).
Conditions
- Non-small Cell Lung Cancer
Interventions
SYS6010Drug
SYS6010
EnlonstobartDrug
Enlonstobart
TislelizumabDrug
administered via Intravenous (IV) injection
Toripalimab ±+platinum-based doublet chemotherapyDrug
Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;
DurvalumabDrug
Durvalumab
PembrolizumabDrug
Pembrolizumab
NivolumabDrug
Nivolumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS) assessed by the independent review committee (IRC)Time frame: Up to approximately 60 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.